CuraGen has announced the initiation of patient dosing in a Phase II clinical trial evaluating a single dose of velafermin for the prevention of oral mucositis (OM).
This clinical trial, the second Phase II study of velafermin, is designed to assess the safety and efficacy of velafermin for the prevention of OM in cancer patients receiving high-dose chemotherapy, with or without radiotherapy, in the setting of autologous bone marrow transplantation (BMT).
